Intractable Pain Clinical Trial
Official title:
Acceptance-Based Treatment for Chronic Pain
Verified date | March 2015 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
The purpose of the study is to test a brief, group-administered psychosocial intervention to reduce interference of pain with daily life, emotional distress, and pain intensity, and improve quality of life and physical activity levels in individuals with chronic pain.
Status | Completed |
Enrollment | 114 |
Est. completion date | September 2009 |
Est. primary completion date | December 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age 18 years old or older; - Proficient in English; - Willing and able to provide written informed consent (proposed informed consent form attached as Appendix A); - Diagnosis of chronic benign pain as a secondary condition associated with a primary impairment due to a traumatic injury or congenital or acquired disorder as verified by a study physician after a medical diagnostic evaluation; - Average pain severity rated > 4/10 with resulting functional limitations; and - Pain duration of at least 6 months. Exclusion Criteria: - Participation in psychotherapy for pain the past 2 months; - Serious, unstable medical illness for which inpatient hospitalization is likely over the next 3 months; and - The following DSM-IV diagnoses or active problems within the past 6 months noted in the patient's CPRS medical record or diagnosed during a structured psychiatric interview: 1) schizophrenia; 2) other psychotic disorder; 3) bipolar disorder; 4) organic mental disorder; 5) borderline or antisocial personality disorder; or 6) alcohol or substance abuse or dependence. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | VA San Diego Healthcare System, San Diego | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Mostoufi SM, Afari N, Ahumada SM, Reis V, Wetherell JL. Health and distress predictors of heart rate variability in fibromyalgia and other forms of chronic pain. J Psychosom Res. 2012 Jan;72(1):39-44. doi: 10.1016/j.jpsychores.2011.05.007. Epub 2011 Jun 3 — View Citation
Wetherell JL, Afari N, Rutledge T, Sorrell JT, Stoddard JA, Petkus AJ, Solomon BC, Lehman DH, Liu L, Lang AJ, Atkinson JH. A randomized, controlled trial of acceptance and commitment therapy and cognitive-behavioral therapy for chronic pain. Pain. 2011 Se — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Brief Pain Inventory | This questionnaire measures pain severity and interference. Scores range from 0-10, with higher scores indicating more pain. | 12 weeks (post treatment) | No |
Secondary | West Haven-Yale Multidimensional Pain Inventory - Activity Subscales | This questionnaire measures levels of activity that can be affected by pain. Full measure has a range of 0-6, with higher scores indicating higher levels of activity. | 12 weeks (post treatment) | No |
Secondary | SF-12 | This questionnaire measures quality of life. Scores range from 0 to 100, with higher scores indicating better quality of life. | 12 weeks (post treatment) | No |
Secondary | Beck Depression Inventory | This questionnaire measures depressive symptoms. Scores range from 0 to 63, with higher scores indicating higher levels of depressive symptoms. | 12 weeks (post treatment) | No |
Secondary | Pain Anxiety Symptom Scale - 20 | This questionnaire measures pain-related anxiety. Scores range from 0 to 100, with higher scores indicating higher levels of anxiety. | 12 weeks (post treatment) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00996983 -
Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer
|
Phase 2 | |
Withdrawn |
NCT03876158 -
Transitioning to a Valve -Gated Intrathecal Drug Delivery System (IDDS)
|
Phase 4 | |
Not yet recruiting |
NCT02522611 -
Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain
|
Phase 1/Phase 2 | |
Recruiting |
NCT04909593 -
Study to Evaluate Automated Intensity Management in Patients Undergoing a BSC SCS Temporary Trial
|
N/A | |
Terminated |
NCT02587130 -
Ketamine and Refractory Painful Care in a Palliative Unit
|
Phase 4 | |
Terminated |
NCT03886753 -
Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products
|
||
Completed |
NCT03082261 -
Multi-center Prospective Study Determining the Sustainability of Pain Relief and Psychosocial and Functional Responses When Utilizing a Multiple Waveform Enabled Neurostimulator
|
N/A | |
Completed |
NCT01854229 -
Prometra Post-Approval Study
|
N/A | |
Completed |
NCT01291901 -
NP2 Enkephalin For Treatment of Intractable Cancer Pain
|
Phase 2 | |
Completed |
NCT00817596 -
Prometra's Utilization in Mitigating Pain (PUMP)
|
N/A | |
Completed |
NCT01567345 -
Intrathecal Morphine Administration Using Implantable Pump With Continuous or Programmable Flow
|
N/A | |
Terminated |
NCT00387244 -
Efficacy of the Spinal Cord Stimulation System as Salvage Therapy
|
N/A | |
Recruiting |
NCT00804154 -
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
|
Phase 1 | |
Approved for marketing |
NCT00866164 -
Prometra's Utilization in Mitigating Pain II
|
N/A |